2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride
CAS : 1019779-04-4
Ref. 3D-FD39560
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté |
Informations sur le produit
2-[(3,4-Difluorophenyl)amino]-N-[2-methyl-5-(1-piperazinylmethyl)phenyl]-acetamide trihydrochloride (SSR180711) is a drug candidate for the treatment of depression. It has been shown that SSR180711 enhances the effects of gamma-aminobutyric acid (GABA) in the brain by inhibiting the GABA transporter. The synergistic effect of SSR180711 with 5-hydroxytryptamine (5-HT), an important neurotransmitter in depression, was also demonstrated in experimental studies. This drug has been shown to have no effect on food intake or weight gain and is unlikely to be addictive.